Prosecution Insights
Last updated: October 02, 2026
Application No. 17/782,388

PEPTIDES THAT ENHANCE NMDA RECEPTOR FUNCTION AND USE THEREOF

Non-Final OA §102
Filed
Jun 03, 2022
Priority
Dec 03, 2019 — provisional 62/942,979 +2 more
Examiner
NIEBAUER, RONALD T
Art Unit
1658
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
University of Pittsburgh
OA Round
3 (Non-Final)
41%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants 41% of resolved cases
41%
Career Allowance Rate
299 granted / 732 resolved
-19.2% vs TC avg
Strong +34% interview lift
Without
With
+34.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
54 currently pending
Career history
798
Total Applications
across all art units

Statute-Specific Performance

§101
7.3%
-32.7% vs TC avg
§103
26.3%
-13.7% vs TC avg
§102
19.6%
-20.4% vs TC avg
§112
29.0%
-11.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 732 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 3/23/26 has been entered. Election/Restrictions and Claim Status Applicants amendments and arguments filed 2/27/26 are acknowledged. Any rejection or objection from the 12/29/25 office action that is not addressed below is withdrawn based on the amendments. Previously, Group 1 and the species of SEQ ID NO:1 were elected. Claims 16 and 20 remain withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 6/24/25. With respect to newly added claim 41, SEQ ID NO:1 was elected, not SEQ ID NO:9 of newly added claim 41. SEQ ID NO:1 does not include modifications as in claim 7. Claims 7 and 41 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 6/24/25. Claims 4-6, 8-11, 13-15, 17-19 and 21-39 have been canceled. Claims 1-3, 12 and 40 are being examined. Priority The priority information is found in the filing receipt dated 10/5/22. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-3, 12 and 40 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Diamond DJ (US 6,632,435; ‘Diamond’). Diamond teach the preparation of a positional scanning synthetic combinatorial library (example 6 columns 15-16). Diamond teach a C-amide synthetic L-amino acid combinatorial nonapeptide library (H-A1-Y9-CONH2) that consisted of 180 mixtures in the OX8 format where O represents one each of the 20 natural L-amino acids and X represents any of the 20 natural amino acids with the exception of cysteine (example 6 columns 15-16). Diamond teach that each mixture consisted of 198 different nonamer peptides (example 6 columns 15-16). In relation to the peptide of claims 1-3 and 40, the nonapeptide library of Diamond is of sequence OX8 where O represents one each of the 20 natural L-amino acids and X represents any of the 20 natural amino acids with the exception of cysteine in each of the remaining positions (example 6 columns 15-16). Diamond teach that each mixture consisted of 198 different nonamer peptides (example 6 columns 15-16). Thus, when O is N (one of the 180 mixtures) , the library necessarily comprises NDSYLRSSL-NH2 (one of the 198 different nonamer peptides) which is instant SEQ ID NO:1. Diamond expressly teach the peptides as synthetic (example 6 columns 15-16). In relation to claim 12, Diamond expressly teach the preparations as mixtures (example 6 columns 15-16). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to RONALD T NIEBAUER whose telephone number is (571)270-3059. The examiner can normally be reached M - F 6:30 - 2:30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melissa Fisher can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. RONALD T. NIEBAUER Primary Examiner Art Unit 1658 /RONALD T NIEBAUER/Examiner, Art Unit 1658
Read full office action

Prosecution Timeline

Show 5 earlier events
Nov 03, 2025
Response Filed
Dec 29, 2025
Final Rejection mailed — §102
Feb 27, 2026
Response after Non-Final Action
Mar 17, 2026
Applicant Interview (Telephonic)
Mar 17, 2026
Examiner Interview Summary
Mar 23, 2026
Request for Continued Examination
Mar 24, 2026
Response after Non-Final Action
Aug 12, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746220
PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF ISCHEMIC CARDIOVASCULAR DISEASE
6y 4m to grant Granted Sep 29, 2026
Patent 12723063
GIPR-AGONIST COMPOUNDS
2y 8m to grant Granted Sep 01, 2026
Patent 12678511
PEPTIDE AND USE THEREOF
4y 9m to grant Granted Jul 14, 2026
Patent 12673135
COLLAGEN-BASED MENISCUS IMPLANTS
4y 6m to grant Granted Jul 07, 2026
Patent 12668610
COMPOUNDS FOR DRUG DELIVERY ACROSS BLOOD-BRAIN BARRIER
3y 6m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
41%
Grant Probability
75%
With Interview (+34.0%)
3y 7m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 732 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month